AiCure has introduced OpenDBM, an open-source version of its computer vision and AI-powered digital biomarker platform. The platform’s framework will give the scientific community access to AiCure’s digital biomarker algorithms and the ability to apply them to their own datasets to measure patient responses to treatment, including facial, vocal and motor characteristics.
AiCure’s digital biomarker platform gathers and analyzes visual and auditory cues directly through a patient’s smartphone camera, pinpointing critical disease characteristics and behavioral trends. Through accurate and consistent data capture, the platform helps to ensure the integrity of clinical trial data throughout a study’s duration.
“While digital biomarkers help to eliminate the blind spots of infrequent and subjective in-person visits, their exclusivity means many in the scientific community are still flying blind when it comes to measuring the impact and validity of these proprietary algorithms, limiting their use and the weight they carry during regulatory conversations,” said Ed Ikeguchi, CEO of AiCure. “AiCure’s OpenDBM opens this black box. Through an open science framework, we hope to unleash the potential of digital biomarkers to not only safeguard the success of a trial and understanding of a drug’s impact, but also better equip sites to offer each patient the support they need.”
Read the full release, here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.